These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 6491914)

  • 1. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects.
    Holazo AA; Colburn WA; Gustafson JH; Young RL; Parsonnet M
    J Pharm Sci; 1984 Aug; 73(8):1108-13. PubMed ID: 6491914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and diuretic effect of bumetanide following intravenous and intramuscular administration to horses.
    Delbeke FT; Debackere M; Desmet N; Stevens M
    J Vet Pharmacol Ther; 1986 Sep; 9(3):310-7. PubMed ID: 3761422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenously administered bumetanide in man.
    Pentikäinen PJ; Neuvonen PJ; Kekki M; Penttilä A
    J Pharmacokinet Biopharm; 1980 Jun; 8(3):219-28. PubMed ID: 7420267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bumetanide and furosemide.
    Brater DC; Chennavasin P; Day B; Burdette A; Anderson S
    Clin Pharmacol Ther; 1983 Aug; 34(2):207-13. PubMed ID: 6872415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure.
    Lau HS; Hyneck ML; Berardi RR; Swartz RD; Smith DE
    Clin Pharmacol Ther; 1986 Jun; 39(6):635-45. PubMed ID: 3709028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics and pharmacodynamics of bumetanide in normal subjects.
    Marcantonio LA; Auld WH; Skellern GG; Howes CA; Murdoch WR; Purohit R
    J Pharmacokinet Biopharm; 1982 Aug; 10(4):393-409. PubMed ID: 7153872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fate of [14C]-bumetanide in man.
    Pentikäinen PJ; Penttilä A; Neuvonen PJ; Gothoni G
    Br J Clin Pharmacol; 1977 Feb; 4(1):39-44. PubMed ID: 843423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and disposition kinetics of HI-6 in Beagle dogs.
    Baggot JD; Buckpitt A; Johnson D; Brennan P; Chung H
    Biopharm Drug Dispos; 1993 Mar; 14(2):93-105. PubMed ID: 8453028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.
    Marcantonio LA; Auld WH; Murdoch WR; Purohit R; Skellern GG; Howes CA
    Br J Clin Pharmacol; 1983 Feb; 15(2):245-52. PubMed ID: 6849758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.
    Kölle EU; Vollmer KO
    Br J Clin Pharmacol; 1986; 22 Suppl 2(Suppl 2):135S-141S. PubMed ID: 3620273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.
    Lee SH; Lee MG; Kim ND
    J Pharmacokinet Biopharm; 1994 Feb; 22(1):1-17. PubMed ID: 8027946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms.
    Rey E; d'Athis P; Richard MO; de Lauture D; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):62-7. PubMed ID: 7061180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.
    Heykants J; Hendriks R; Meuldermans W; Michiels M; Scheygrond H; Reyntjens H
    Eur J Drug Metab Pharmacokinet; 1981; 6(1):61-70. PubMed ID: 7250152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute bioavailability and noncompartmental analysis of intravenous and intramuscular Cefotan (cefotetan) in normal volunteers.
    Zimmerman J; Cohen A; Thyrum P
    J Clin Pharmacol; 1989 Feb; 29(2):151-7. PubMed ID: 2715372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of bumetanide in grossly oedematous patients.
    Bailie GR; Grennan A; Waldek S
    Clin Pharmacokinet; 1987 Jun; 12(6):440-3. PubMed ID: 3608345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment.
    Howlett MR; Skellern GG; Auld WH; Murdoch WR
    Eur J Clin Pharmacol; 1990; 38(6):583-6. PubMed ID: 2373133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of neomycin in sheep after intravenous, intramuscular, subcutaneous and intratracheal administration.
    Errecalde JO; Lanusse CE; Landoni MF
    Zentralbl Veterinarmed A; 1990 Apr; 37(3):163-9. PubMed ID: 2114710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of bumetanide in the newborn infant.
    Lopez-Samblas AM; Adams JA; Goldberg RN; Modi MW
    Biol Neonate; 1997; 72(5):265-72. PubMed ID: 9395836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.